Advisor Group’s Spyre Therapeutics SYRE Stock Holding History

Advisor Group’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-28	Closed	-$5K	–	5321
2018 Q4	$5K	Hold	28	–	–	﹤0.01%	4533
2018 Q3	$7K	Buy	+28	New	+$6.54K	﹤0.01%	4466

Other funds holding SYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Advisor Group's SYRE Position: Q1 2019 in Review

Advisor Group sold out of Spyre Therapeutics (SYRE) in Q1 2019, closing a stake of 28 shares — an estimated $5K sold.

Advisor Group first reported a position in SYRE in Q3 2018 and held it in 2 quarters. The position peaked at $7K in Q3 2018. 71 funds tracked by Wall St. Rank hold SYRE as of Q1 2019.

Advisor Group reported no remaining Spyre Therapeutics position as of Q1 2019 after selling out during the quarter.
Advisor Group sold 28 Spyre Therapeutics shares in Q1 2019, an estimated $5K.
Advisor Group first reported a position in Spyre Therapeutics in Q3 2018 and held it in 2 quarters.
Advisor Group's Spyre Therapeutics position peaked at $7K in Q3 2018.
71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2019.

Based on Advisor Group's 13F filing for Q1 2019, filed 9 May 2019.